Overview

Minagene’s test utilizes targeted next-generation sequencing and array-based platforms to comprehensively detect somatic mutations, chromosomal rearrangements, and gene expression signatures in leukemia, lymphoma and myeloma specimens.

Methodology

DNA and RNA are extracted from bone marrow, peripheral blood or tissue samples and processed for hybrid capture-based targeted sequencing of over 300 genes recurrently implicated in hematological cancers. Custom FISH/aCGH panels interrogate recurring translocations.

Key Highlights of Minagene’s Molecular Testing for Hematological Malignancies

-Establishes definitive diagnoses for ambiguous morphologies

-Determines prognostic risk stratification and subtype classification

-Identifies targets for specific small molecule inhibitors and immunotherapies

-Monitors for minimal residual disease during and after treatment

-Features a CLIA-certified, CAP-accredited laboratory

By applying a multimodal genomic approach, clinicians can optimize therapeutic strategies from diagnosis through remission monitoring. Comprehensive mutational profiling assists clinical decision-making at all stages of care.

When to Consider Minagene’s Molecular Testing for Hematological Malignancies

Physicians should order Minagene’s molecular testing at initial workup of suspected hematological cancers as well as during surveillance and relapse to elucidate resistance mechanisms, guide clinical trial selection, and personalize management.